Seattle Genetics, Takeda lymphoma drug succeeds late-stage trial

(Reuters) - Seattle Genetics Inc and Japan's Takeda Pharmaceutical Co Ltd said on Monday that their drug met the main goal in a late-stage study of helping blood cancer patients live longer without their condition worsening.